Meropenem pharmacokinetics in a patient with multiorgan failure from meningococcemia undergoing continuous venovenous hemodiafiltration

American Journal of Kidney Diseases

Volumn 33, Issue 4, 1999, Pages 790-795

  Meyer, M M ^a   Munar, M Y ^a   Kohlhepp, S J ^a   Bryant, R E ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Continuous venovenous hemodiafiltration; Dosing; Meningococcal meningitis; Meningococcemia; Meropenem; Pharmacokinetics

Indexed keywords

CARBAPENEM; CILASTATIN PLUS IMIPENEM; MEROPENEM;

ADULT; ARTICLE; CASE REPORT; DOSE RESPONSE; DRUG CLEARANCE; DRUG ELIMINATION; EPIDEMIC MENINGITIS; HEMOFILTRATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MALE; MENINGOCOCCEMIA; MULTIPLE ORGAN FAILURE; NEISSERIA MENINGITIDIS; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0032925665     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(99)70236-2     Document Type: Article

References (18)

1. DH Pitkin W Sheikh HL Nadler Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American Centers Clin Infect Dis 24 suppl 2 1997 S238 S248
2. LR Wiseman AJ Wagstaff RN Brogden HM Bryson Meropenem: A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy Drugs 50 1995 73 101
3. CE Nord A Lindmark I Persson Susceptibility of anaerobic bacteria to meropenem J Antimicrob Chemother 24 suppl A 1989 S113 S117
4. A Leroy JP Fillastre F Borsa-Lebas I Etienne G Humbert Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment Antimicrob Agents Chemother 36 1992 2794 2798
5. BA Christensson I Nilsson-Ehle M Hutchison SJ Haworth B Oqvist SR Norrby Pharmacokinetics of meropenem in subjects with various degrees of renal impairment Antimicrob Agents Chemother 36 1992 1532 1537
6. M Chimata M Nagase Y Suzuki M Shimomura S Kakuta Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease Antimicrob Agents Chemother 37 1993 229 233
7. JW Mouton JN van den Anker Meropenem clinical pharmacokinetics Clin Pharmacokinet 28 1996 275 286
8. MP Harrison SJ Haworth SR Moss DM Wilkinson A Featherstone The disposition and metabolic fate of 14C-meropenem in man Xenobiotics 23 1993 1311 1323
9. YSK Moon KC Chung MA Gill Pharmacokinetics of meropenem in animals, healthy volunteers, and patients Clin Infect Dis 24 suppl 2 1997 S249 S255
10. KP Klugman R Dagan the Meropenem Meningitis Study Group Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis Antimicrob Agents Chemother 39 1995 1140 1146
11. RE Condon AP Walker CB Hanna RN Greenberg A Broom D Pitkin Penetration of meropenem in plasma and abdominal tissues from patients undergoing intraabdominal surgery Clin Infect Dis 24 suppl 2 1997 S181 S183
12. P Kempf A Bauerfeind A Muller J Blum Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections Infection 24 1996 473 479
13. H Elkhaili S Niedergang D Pompei L Linger D Leveque F Jehl High-performance liquid chromatography assay for meropenem in serum J Chromatogr 686 1996 19 26
14. SK Bickley Drug dosing during continuous arteriovenous hemofiltration Clin Pharm 7 1988 198 206
15. th International Congress of Chemotherapy pp 210 Abs 5332, 1997. Sydney 29 June - 3 July 1997
16. DN Fish TJ Singletary Meropenem, a new carbapenem antibiotic Pharmacotherapy 17 1997 644 669
17. WA Craig The pharmacology of meropenem, a new carbapenem antibiotic Clin Infect Dis 24 suppl 2 1997 S266 S275
18. WM Bennett GR Aronoff TA Golper G Morrison DC Brater I Singer Drug prescribing in renal failure, in Dosing Guidelines for Adults ed 3 1994 American College of Physicians Philadelphia, PA 26